Quality of Life With Arcoxia in Women With Dysmenorrhea (0663-094)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

337 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-09-01

Study Completion Date

2006-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Allow gynecologists to gain experience with arcoxia for treatment of dysmenorrhea.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Analgesic Treatment Mediated by Arcoxia (0663-093)

NCT00380523

Pain

COMPLETED PHASE4

An Investigational Drug Study in the Treatment of Primary Dysmenorrhea (0663-064)

NCT00092729

Dysmenorrhea

COMPLETED PHASE3

Pain Post Abdominal Laparoscopy Prevention With Arcoxia

NCT00565682

Laparoscopic Surgery for Appendicitis Laparoscopic Surgery for Cholecystitis Laparoscopic Surgery for Ovarian Cysts

COMPLETED PHASE4

A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)

NCT00788710

Acute Pain Following a Total Abdominal Hysterectomy

COMPLETED PHASE3

Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)

NCT00820027

Pain, Postoperative

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy women older than 18 years old and younger than 25 years old
* Voluntary agreement to participate in the study and signature of informed consent
* Women with clinical diagnosis of dysmenorrhea

Exclusion Criteria

* Diagnosis of secondary dysmenorrhea due to: endometriosis, adenomyosis, malformations of Muller's conducts, uterine fibromyomas, ovarian cystic, pelvic varicocoele, inflammatory pelvic disease, adherences, intrauterine devices, cervical channel stenosis, etc.
* Patients with diagnosis of acute inflammatory abdomen
* Patients with diagnosis of congestive heart disease, stroke (1 year), unstable angina, and history of myocardial infarction
* Women auto prescribing rescue medication for dysmenorrheal pain during the study
* Women with a diagnosis of mild dysmenorrhea

Minimum Eligible Age

18 Years

Maximum Eligible Age

25 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No